Eli Lilly and Company announced results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study, which evaluates the efficacy and safety of Kisunla (donanemab-azbt) in individuals with early symptomatic Alzheimer's disease. The findings indicate that Kisunla continues to demonstrate a growing benefit over three years, as it slows cognitive decline compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative. The study highlights the importance of early intervention, showing that earlier initiation of Kisunla significantly reduces the risk of disease progression. These results were presented at the 2025 Alzheimer's Association International Conference in Toronto.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.